

FOR IMMEDIATE RELEASE

**IntegraGen Presents Data at ESMO 2014 Confirming that its microRNA Biomarker Predicts Survival in Patients with Metastatic Colorectal Cancer**

*Expression of hsa-miR-31-3p shown to predict impact of anti-EGFR therapy on progression free survival in all-RAS wild-type patients with metastatic colorectal cancer*

Madrid, Spain (September 29, 2014) - IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced that it [presented data](#) confirming that the oncology biomarker miR-31-3p is predictive of cetuximab effects in all-RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients during the European Society for Medical Oncology (ESMO) 2014 Congress being held from September 26<sup>th</sup> to 30<sup>th</sup> in Madrid, Spain. The data presented was based on a post-hoc analysis of patients enrolled in the [New EPOC](#) phase III trial who were randomized to receive chemotherapy alone or chemotherapy plus cetuximab before and after resection of colorectal liver metastasis. These results confirm those previously presented at ASCO 2014 this past June in Chicago.

The results of the study presented during the ESMO Congress showed the outcome of mCRC patients treated with chemotherapy plus cetuximab differed according to the expression level of miR-31-3p. Among patients with high expression of miR-31-3p, those treated with the combination of chemotherapy plus cetuximab had a shorter progression free survival compared to patients treated with chemotherapy alone. However, when only patients with a low expression level of miR-31-3p were considered, the progression free survival was no worse with the addition of cetuximab. The analysis was focused on patients who did not carry a *RAS* gene (*KRAS* or *NRAS*) mutation.

“With the use of extended *RAS* testing to identify mCRC patients who are candidates for treatments targeting the epidermal growth factor receptor (EGFR), there is a need to identify additional biomarkers which predict patient response to EGFR inhibitors in all-*RAS* wild-type patients,” stated study co-author Dr. John Primrose, Professor of Surgery at the University of Southampton and Chief Investigator for the New EPOC Study. “The results of our study demonstrate that all-*RAS* wild-type mCRC patients with high expression levels of miR-31-3p experience inferior progression free survival when treated with the combination of chemotherapy plus cetuximab.”

“We believe that measuring the expression of this biomarker, which IntegraGen holds worldwide rights for, will benefit patients, oncologists and payers by increasing the ability to provide a personalized treatment approach to cancer care which avoids ineffective and costly drug therapy and its associated toxicities while also allowing for the earlier utilization of alternative treatment options which may be more effective,” said Bernard Courtieu, IntegraGen’s CEO. “The results of this study add to our [previously published](#) research with miR-31-3p and further demonstrates the potential clinical utility of this single microRNA biomarker to predict the impact of anti-EGFR therapy in all-*RAS* wild-type metastatic colorectal cancer patients. We are currently in discussions with several potential laboratory partners relative to offering a commercial test to clinicians based on the miR-31-3p biomarker.”

IntegraGen obtained the exclusive license for the worldwide rights for the miR-31-3p biomarker from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique - Hopitaux de Paris, all leading French academic institutions which, along with IntegraGen, are co-owners of the patent. The New EPOC Study is funded by [Cancer Research UK](#) (clinical trial number CRUK/06/031).

## **ABOUT INTEGRAGEN**

Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests in the fields of autism and oncology. IntegraGen's mission is to translate molecular research into clinical practice through the identification of novel genetic biomarkers and the subsequent development of molecular diagnostic tests which allow clinicians to better manage the clinical care of their patients. IntegraGen is also a leader in delivering expert genomic service solutions to academic researchers and life sciences companies as a result of its scientific knowledge and technological expertise related to cutting edge genomic platforms and bioinformatics.

For more information on IntegraGen visit [www.integragen.com](http://www.integragen.com).

## **CONTACTS**

### **INTEGRAGEN**

Bernard COURTIEU  
President, Managing Director

Laurence RIOT LAMOTTE  
CFO  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel.: +33 (0)1 60 91 09 00

### **NEWCAP.**

#### **Investor and Media relations**

Emmanuel HUYNH  
Louis-Victor DELOUVRIER  
[integragen@newcap.fr](mailto:integragen@newcap.fr)  
Tel.: +33 (0)1 44 71 94 94